ASCO17 Archives -

The cost of cancer drugs became a major talking point at this year’s ASCO conference, where doctors raised

High cost of cancer drugs takes centre stage at ASCO

https://pharmaphorum.com/news/high-cost-cancer-drugs-takes-centre-stage-asco/

ASCO serves up shock as Roche’s data disappoints

Puma gains as Roche breast cancer combo disappoints

https://pharmaphorum.com/news/puma-gains-roche-breast-cancer-combo-disappoints/

While ASCO often showcases the benefits of new cancer therapies, it was a well-established drug that proved to

ASCO round up: Zytiga shines in frontline prostate role, Loxo and Incyte pass early tests

https://pharmaphorum.com/news/asco-data-points-zytiga/

Data sets AZ up to file Lynparza in new indication

Lynparza first PARP drug to show promise in breast cancer

https://pharmaphorum.com/news/lynparza-first-parp-drug-show-promise-breast-cancer/

A combination of Novartis’ ‘next generation’ CAR-T drug CTL119 with Janssen and AbbVie’s Imbruvica has cleared all signs

Spectacular early results for Novartis’ CAR-T combined with Imbruvica

https://pharmaphorum.com/news/spectacular-early-results-novartis-car-t-combined-imbruvica/

Tesara and Takeda among other companies to publish data.

AZ highlights data from next-gen oncology drugs at ASCO

https://pharmaphorum.com/news/az-highlights-data-next-gen-oncology-drugs-asco/

Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.

ASCO 2017: Breast cancer next target for Keytruda

https://pharmaphorum.com/views-and-analysis/asco-2017-breast-cancer-keytruda/

ASCO17